Clinical trial NCT00013585 - References

HIV Infections — Safety and Effectiveness of the Selegiline "Patch" for Decreased Mental Function in HIV Patients

Citation(s)

•   Bell JE
  An update on the neuropathology of HIV in the HAART era. Histopathology. 2004 Dec;45(6):549-59. Review.
•   Evans SR, Yeh TM, Sacktor N, Clifford DB, Simpson D, Miller EN, Ellis RJ, Valcour V, Marra CM, Millar L, Schifitto G; AIDS Clinical Trials Group and the Neurologic AIDS Research Consortium
  Selegiline transdermal system (STS) for HIV-associated cognitive
•   Koutsilieri E, Scheller C, ter Meulen V, Riederer P
  Monoamine oxidase inhibition and CNS immunodeficiency infection. Neurotoxicology. 2004 Jan;25(1-2):267-70. Review.
•   McArthur JC
  HIV dementia: an evolving disease. J Neuroimmunol. 2004 Dec;157(1-2):3-10. Review.
•   Sacktor N, Schifitto G, McDermott MP, Marder K, McArthur JC, Kieburtz K
  Transdermal selegiline in HIV-associated cognitive impairment: pilot, placebo-controlled study. Neurology. 2000 Jan 11;54(1):233-5.
•   Schifitto G, Deng L, Yeh TM, Evans SR, Ernst T, Zhong J, Clifford D
  Clinical, laboratory, and neuroimaging characteristics of fatigue in HIV-infected individuals. J Neurovirol. 2011 Feb;17(1):17-25. doi: 10.1007/s13365-010-0010-5. Epub 2010 Dec 23.
•   Schifitto G, Kieburtz K, McDermott MP, McArthur J, Marder K, Sacktor N, Palumbo D, Selnes O, Stern Y, Epstein L, Albert S
  Clinical trials in HIV-associated cognitive impairment: cognitive and functional outcomes. Neurology. 2001 Feb 13;56(3):415-8.

Phase II, Placebo-Controlled, Double-Blind Study of the Selegiline Transdermal System (STS) in the Treatment of HIV-Associated Cognitive Impairment

Details for clinical trial NCT00013585